Compare Neurocrine Biosciences Inc (NBIX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Waste Management, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Waste Management, Inc. trades at $233.17 (market cap $96.00B). The key difference: Waste Management, Inc. is far larger — about 5.5× Neurocrine Biosciences Inc's market cap, and Waste Management, Inc. pays a 1.48% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WM | |
|---|---|---|
Market Cap | $17.40B | $96.00B |
Sector | Health | Industrials |
52-Week High | $180.55 | $246.51 |
52-Week Low | $123.10 | $196.77 |
Enterprise Value | $16.49B | $118.73B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
WM (Waste Management) trades at $233.18, down 2.56% on the day, but remains near its 52-week high of $248.13. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal steady revenue growth to $25.20 billion in 2025 and a robust 10.99% net income margin. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 results missed. Analyst sentiment is positive with a consensus buy rating and $263.57 price target, supported by a reliable dividend and strong cash flow from operations of $6.04 billion.
Outlook: WM's dominant market position, pricing power, and renewable energy initiatives support long-term growth, but high debt levels and competitive pressures pose risks. The stock offers value for income and growth investors, with potential upside to analyst targets if execution remains solid amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
